[16]. In contrast, the larger study from France including 143 patients demonstrated that HBsAg decline during TDF therapy was influenced by HIV induced immunodeficiency [17]. In HBeAg positive patients, HBsAg decline was significantly slower in patients with CD4 T-cell count <350/mm3. This evidence concerns the gene CD4 and immunodeficiency disease.